6020 QUALITY ASSURANCE/QUALITY CONTROL*

6020 A. Introduction

Without quality control (QC) results, there is no confidence in the results of analytical tests. As described in Part 1000, essential QC measures include method calibration, reagent standardization, assessment of each analyst’s capabilities, analysis of blind check samples, determination of the method’s sensitivity (method detection level or quantification limit), and daily evaluation of bias, precision, and the presence of laboratory contamination or other analytical interference. The details of these procedures, their performance frequency, and expected ranges of results should be formalized in a written Quality Assurance Manual and standard operating procedures (SOPs).

Some of the methods in Part 6000 include specific QC procedures, frequencies, and acceptance criteria. These are considered the minimum quality controls needed to perform the method successfully; additional QC procedures can and should be used. If the QC criteria listed in this section exceed those listed in the individual methods, the criteria in this section must also be included. Some regulatory programs may require further QC or have alternative acceptance limits.

Each method typically includes acceptance-criteria guidance for precision and bias of test results. If not, the laboratory should determine its own criteria via control-charting techniques. Evaluate bias using recoveries from laboratory-fortified blanks (LFBs). Evaluate precision by analyzing duplicate or spiked duplicate samples. Additional acceptance criteria guidance may be provided by program- or project-specific requirements.

To help verify the accuracy of calibration standards and overall method performance, participate in an annual or preferably semi-annual analytical program of single-blind QC check samples (QCS), ideally provided by an external entity. Such programs are sometimes called proficiency testing (PT)/performance evaluation (PE) studies. An unacceptable result on a PT sample is often a strong indication that a test protocol is not being followed successfully. Investigate circumstances fully to find the cause. In many jurisdictions, participation in PT studies is a required part of laboratory certification/accréditation.

6020 B. Quality Control Practices

1. Initial Quality Control

a. Initial demonstration of capability (IDC): Before new analysts run any samples, verify their capability with the method (see Section 1020B.1 for specifics). Run at least four LFBs (6020B.2e) and compare results to the limits listed in the method. All instrument performance checks and calibration requirements must be met before analysis. (NOTE: Analysis and evaluation of a method blank is required.) If no limit is specified, use the following procedure to establish initial limits:

Calculate the standard deviation of the four samples. The LFB’s recovery limits are

\[ LFB’s \text{ initial recovery limits} = \text{Mean} \pm (5.84 \times \text{Standard Deviation}) \]

where:

\[ 5.84 = \text{the two-sided Student’s } t \text{ factor for } 99\% \text{ confidence limit for three degrees of freedom.}^3 \]

While this process will provide initial limits, they should be considered temporary. Limits developed from more replicates (e.g., at least 20) will give a better determination of accuracy and precision. (For basic guidance on demonstrating capability, see Section 1020B.1 and 3.)

b. Method detection level (MDL): If data will be reported below the calibrated range, then before analyzing samples, determine the MDL for each analyte via Section 1020B.4 or other applicable procedures.\(^2\) MDL determination and verification are not required if 1) data are not reported below the instrument’s calibrated range, and 2) the ability to provide quantitative data at the reporting limit is verified. Determine MDL for each analyte in a method and matrix category. The laboratory should define all matrix categories in its QA plan. Perform a new MDL determination whenever changes in the method’s instruments or operating conditions may affect sensitivity. Ideally, samples for MDL determinations should be analyzed over at least a 3-d period to generate a more realistic value. Include all sample-preparation steps in the MDL determination.

Ideally, use pooled data from several analysts rather than data from one analyst to determine overall lab MDLs. (For specific information on MDLs and pooling, see Section 1020B.11)

Verify the MDL on each instrument used in the laboratory by analyzing a QC sample (subjected to all sample-preparation steps) spiked at a level 1 to 4 times the MDL. A successful verification is one that meets all the method’s detection criteria. Repeat the verification at least annually.

c. Operational range: Before using a new method or instrument, determine its operational range (upper and lower limits), or at least verify that the intended range of use is within the operational range. For each analyte, use standard concentrations that provide increasing instrument response. The minimum reporting level (MRL) is set to a concentration at or above the lowest standard used in the analysis. Quantitation at the MRL

---

John R. Gumpper, Andrew D. Eaton.
must be verified initially and at least quarterly (preferably daily) by analyzing a QC sample (subjected to all sample-preparation steps) spiked at a level 1 to 2 times the MRL. A successful verification meets the method’s or laboratory’s accuracy requirements at the MRL. Laboratories must define acceptance criteria for the operational range, including the MRL, in their QA documentation.

2. Ongoing Quality Control

   a. Calibration: Initially calibrate with at least five non-zero calibration standards of the analyte(s) of interest. If using second-order fits, include at least six non-zero standards.

   Select calibration standards that bracket the sample’s expected concentration and are within the method’s operational range. The number of calibration points depends on the width of the operational range and the shape of the calibration curve. One calibration standard must be at or below the method’s reporting limit.

   As a general rule, the range of standard concentrations should not be greater than three orders of magnitude, and may be much less. For example, concentration variables of 1, 5, 10, 50, and 100 can be used if the operational range is two orders of magnitude.

   Apply response-factor, linear, or quadratic curve-fitting statistics, as appropriate, to analyze the concentration–instrument response relationship. If the relative standard deviation of the response factors is ≤15%, then the average response factor may be used. Otherwise, use a regression equation. The appropriate linear or nonlinear correlation coefficient for standard concentration-to-instrument response should be greater than or equal to 0.995 for linear calibrations and 0.990 for quadratic calibrations. Weighting factors (e.g., 1/x or 1/x²) may be used to give more weight to the lower concentration points of the calibration.

   Back calculate each calibration point’s concentration. The back-calculated and true concentrations should agree within ±30% for points above the MRL and ±50% at ≤MRL, unless different criteria are specified in an individual method.

   Use initial calibration to quantify analyte concentrations in samples. Use calibration verification only to check the initial calibration, not to quantify samples. Repeat initial calibration at least annually or when calibration verification criteria cannot be met. (For basic calibration guidance, see Section 1020B.)

   b. Calibration verification: Verify calibration by periodically analyzing a continuing calibration standard during a run. If not specified otherwise in the individual method, analyze after each 20 samples and at the end of the run. Analyses employing internal standards may omit the verification at the end of the run. The calibration verification standard’s analyte concentration may be varied over the calibration range to determine detector response. Some methods may also require the analysis of an instrument blank after the continuing calibration standard.

   For the calibration verification to be valid, check standard results must not exceed the limits specified in the method or in Table 6020.1 (if not specified in the method).

   If a calibration verification fails, immediately cease analyzing samples and take corrective action. Often, the problem can be fixed by performing injector maintenance or trimming a few cm from the front of the column. Then, re-analyze the calibration verification. If the calibration verification passes, continue the analysis. Otherwise, repeat initial calibration and re-analyze samples run since the last acceptable calibration verification.

   If the LFB is not prepared from a second source to confirm method accuracy, the laboratory must also verify the accuracy of its standard preparation by analyzing a mid-level second-source calibration standard whenever a new initial calibration curve is prepared. Results must agree within 25%, unless otherwise specified in a method. (A second source is either from another vendor or a completely different lot from the same vendor. If neither option is feasible, then the second-source calibration standard must be prepared from primary stock materials by a different analyst.)

   c. Quality control sample (QCS): Analyze an externally generated, blind QCS (unknown concentration) at least annually (preferably semi-annually or quarterly). Obtain this sample from a source external to the laboratory, and compare results to that laboratory’s acceptance results. If testing results do not pass acceptance criteria, investigate why, take corrective action, and analyze a new QCS. Repeat this process until results meet acceptance criteria. Record all attempts to meet criteria. Multiple failures indicate problems with method operation. External proficiency test (PT) samples meet this criterion.

   d. Method blank (MB): Include at least one MB daily or with each batch of 20 or fewer samples, whichever is more frequent. Prepare and analyze the MB in exactly the same manner as field samples, including all preparation and cleanup steps, and all preservatives used in samples. Any constituent(s) recovered must generally be less than or equal to one-half the reporting level (unless the method specifies otherwise). If any MB measurements are at or above one-half the reporting level (if reporting to MRL) or greater than the MDL (if reporting to the MDL), take immediate corrective action (as outlined in Section 1020B.5). This may include re-analyzing the sample batch or qualifying the reported data. Sample results that are below the MRL are considered valid even if the MB has a detection above the MRL, but should be qualified for information purposes. For common lab contaminants, such as methylene chloride, a lab may need to use a higher MRL to meet the MB criteria.

   e. Laboratory-fortified blank (LFB): The LFB and LFM may be made from the same source standard as the initial calibration or from a second source. If the LFB and LFM are from the same source as the ICAL, the ICAL must be verified using a second source standard (see 6020B.2b).

   Using stock solutions, prepare fortified concentrations so they are within the calibration curve. Prepare at least one LFB each day samples are prepared or with each preparation batch of 20 or fewer samples, whichever is more frequent. Prepare and analyze the LFB in exactly the same manner as the field samples, including all preparation and cleanup steps and all preservatives.

   Calculate percent recovery and determine control limits (Section 1020B) for these measurements. Some methods may have specific limits to use in lieu of plotting control charts. In those cases, control charts may still be useful in identifying potential problems but are not required. Ensure that the LFB meets the method’s performance criteria when such criteria are specified. If the LFB does not meet the acceptance criteria, the method is out of control; take corrective action. Re-prepare and re-analyze as samples with an acceptable LFB. If impossible, qualify the reported data.
<table>
<thead>
<tr>
<th>Section</th>
<th>Constituent Concentration by Gas Extraction</th>
<th>MB</th>
<th>LFB*</th>
<th>LFM†, LFMD‡</th>
<th>Surrogate</th>
<th>ISTD</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>6040B</td>
<td>§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6040C</td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6040D</td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6040E</td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6200B</td>
<td>Volatile Organic Compounds</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6200C</td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6211B</td>
<td>Methane</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6211C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6231B</td>
<td>EDB &amp; DBCP</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4</td>
</tr>
<tr>
<td>6231C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6231D</td>
<td></td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4</td>
</tr>
<tr>
<td>6232B</td>
<td>THMs and Chlorinated Organic Solvents</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>6232C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6232D</td>
<td></td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6251B</td>
<td>DBPs: HAAs and Trichlorophenol</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>6252B</td>
<td>DBP: Aldehydes</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>#</td>
</tr>
<tr>
<td>6410B</td>
<td>Extractable Base/Neutrals and Acids</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>2,3</td>
</tr>
<tr>
<td>6420B</td>
<td>Phenols</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>x</td>
</tr>
<tr>
<td>6420C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>2,3</td>
</tr>
<tr>
<td>6431B</td>
<td>PCBs</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6431C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>6440B</td>
<td>Polynuclear Aromatic Hydrocarbons</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6440C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6450B</td>
<td>Nitrosamines</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>1</td>
</tr>
<tr>
<td>6450C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>1</td>
</tr>
<tr>
<td>6610B</td>
<td>Carbamate Pesticides</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>6630B</td>
<td>Organochlorine Pesticides</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6630C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>4</td>
</tr>
<tr>
<td>6630D</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>4</td>
</tr>
<tr>
<td>6640B</td>
<td>Acidic Herbicide Compounds</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>6651B</td>
<td>Glyphosate Herbicide</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6710B</td>
<td>Tributyl Tin</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>6710C</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
</tbody>
</table>

* Laboratory-fortified blank.
† Laboratory-fortified matrix.
‡ Laboratory-fortified matrix duplicate.
§ LFM + Dup OK
|| Optional
# Confirm optional
1. Additional QC guidelines in method.
2. Gas chromatography/mass spectrometer (GC/MS) tuning required.
3. Chromatography checks required.
4. Second-column confirmation or GC/MS confirmation required.
f. Laboratory-fortified matrix (LFM)/Laboratory-fortified matrix duplicate (LFMD): Prepare at least one LFM/LFMD each day samples are prepared or with each preparation batch of 20 or fewer samples. (For basic guidance on LFM and LFMDs, see Section 1020B.7 and 8.) Some regulatory programs require more frequent use of LFM. When analytes of interest are expected to be present, the laboratory may substitute a duplicate analysis for the LFMD. If the client does not provide enough sample volume for the LFM/LFMD analyses, the laboratory may perform duplicate LFB analyses to generate precision data for the analysis.

To prepare an LFM, add a known concentration of analytes to a randomly selected routine sample without increasing its volume by more than 1%. Otherwise, account for the dilution mathematically. Ideally, the new concentration should be at or below the midpoint of the calibration curve. Spike all analytes of interest to the client. Process the LFM and LFMD as separate samples through entire sample preparation and analysis. If necessary, dilute the spiked sample at analysis to bring the measurement within the calibration curve.

Calculate percent recovery and relative percent difference, plot control charts (unless the method specifies acceptance criteria), and determine control limits for spikes (Section 1020B). Ensure that the method’s acceptance criteria are satisfied. If the LFB met acceptance criteria, failures usually indicate problems created by the sample matrix. If the native analyte concentration is more than four times (4×) greater than the spike concentration, spike recoveries may be unreliable. Precision data may still be usable based on the total analyte concentration (native + spike).

\[ \text{Percent Recovery} = \left( \frac{C_s}{C_f} \right) \times 100 \]

\[ \text{Relative Percent Difference} = \left( \frac{|S - C|}{S} \right) \times 100 \]

Where:
- \( C_s \): LFM concentration determined experimentally,
- \( f \): spike dilution correction,
- \( C \): concentration of sample before spiking, and
- \( S \): concentration of spike.

f. Laboratory-fortified matrix (LFM)/Laboratory-fortified matrix duplicate (LFMD): Prepare at least one LFM/LFMD each day samples are prepared or with each preparation batch of 20 or fewer samples. (For basic guidance on LFM and LFMDs, see Section 1020B.7 and 8.) Some regulatory programs require more frequent use of LFM. When analytes of interest are expected to be present, the laboratory may substitute a duplicate analysis for the LFMD. If the client does not provide enough sample volume for the LFM/LFMD analyses, the laboratory may perform duplicate LFB analyses to generate precision data for the analysis.

To prepare an LFM, add a known concentration of analytes to a randomly selected routine sample without increasing its volume by more than 1%. Otherwise, account for the dilution mathematically. Ideally, the new concentration should be at or below the midpoint of the calibration curve. Spike all analytes of interest to the client. Process the LFM and LFMD as separate samples through entire sample preparation and analysis. If necessary, dilute the spiked sample at analysis to bring the measurement within the calibration curve.

Calculate percent recovery and relative percent difference, plot control charts (unless the method specifies acceptance criteria), and determine control limits for spikes (Section 1020B). Ensure that the method’s acceptance criteria are satisfied. If the LFB met acceptance criteria, failures usually indicate problems created by the sample matrix. If the native analyte concentration is more than four times (4×) greater than the spike concentration, spike recoveries may be unreliable. Precision data may still be usable based on the total analyte concentration (native + spike).

\[ \text{Percent Recovery} = \left( \frac{C_s}{C_f} \right) \times 100 \]

\[ \text{Relative Percent Difference} = \left( \frac{|S - C|}{S} \right) \times 100 \]

Where:
- \( C_s \): LFM concentration determined experimentally,
- \( f \): spike dilution correction,
- \( C \): concentration of sample before spiking, and
- \( S \): concentration of spike.

\[ \text{Percent Recovery} = \left( \frac{C_s \times f}{C} \right) \times 100 = \% \text{Recovery LFM or LFMD} \]

where:
- \( C_s \): LFM concentration determined experimentally,
- \( f \): spike dilution correction,
- \( C \): concentration of sample before spiking, and
- \( S \): concentration of spike.

3. Calculations

\[ \text{a. LFM recovery:} \]

\[ \left( \frac{C_s \times f}{C} \right) \times 100 = \% \text{Recovery LFM or LFMD} \]

where:
- \( C_s \): LFM concentration determined experimentally,
- \( f \): spike dilution correction,
- \( C \): concentration of sample before spiking, and
- \( S \): concentration of spike.
NOTE: $f$ should be greater than 0.95. More than 5% dilution due to spiking changes the matrix significantly. Ideally, keep $f$ to above 0.99 (equivalent to 1% dilution of sample due to spike addition), in which case $f$ can be ignored and the equation simplified to eliminate $f$.

b. LFB and surrogate recovery:

$$\frac{C_b}{I} \times 100 = \% \text{ Recovery LFB}$$

where:

- $C_b =$ LFB or surrogate concentration determined experimentally,
- $I =$ initial concentration of analytes (or surrogate) added to LFB or sample.

c. Relative percent difference:

$$\left( \frac{|LFM - LFMD|}{|LFM + LFMD|} \right) \times 100 = \% \text{ RPD}$$

or

$$\left( \frac{|D_1 - D_2|}{\frac{D_1 + D_2}{2}} \right) \times 100 = \% \text{ RPD}$$

where:

- $LFM =$ concentration determined for LFM,
- $LFMD =$ concentration determined for LFMD,
- $D_1 =$ concentration determined for first duplicate, and
- $D_2 =$ concentration determined for second duplicate.

4. References